Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Lucid Diagnostics Inc shares valued at $242,292 were purchased by Matheis Dennis on May 20 ’25. At $1.29 per share, Matheis Dennis acquired 187,098 shares. The insider’s holdings grew to 187,098 shares worth approximately $0.25 million following the completion of this transaction.
Also, Matheis Dennis purchased 129,684 shares, netting a total of over 171,520 in proceeds. Following the buying of shares at $1.32 each, the insider now holds 316,782 shares.
Before that, Matheis Dennis had added 33,218 shares to its account. In a trade valued at $43,795, the Director bought Lucid Diagnostics Inc shares for $1.32 each. Upon closing the transaction, the insider’s holdings increased to 33,218 shares, worth approximately $0.47 million.
As published in their initiating research note from Ascendiant Capital Markets on December 27, 2021, Lucid Diagnostics Inc [LUCD] has been a Buy and the price target has been revised to $16. Analysts at Needham started covering the stock with ‘”a Buy”‘ outlook in a report released in early November. As of November 08, 2021, Cantor Fitzgerald has initiated its “an Overweight” rating for LUCD. Earlier on November 08, 2021, BTIG Research initiated its rating. Their recommendation was “a Buy” for LUCD stock.
Analyzing LUCD Stock Performance
During the last five days, there has been a surge of approximately 8.13%. Over the course of the year, Lucid Diagnostics Inc shares have jumped approximately 62.45%. Shares of the company reached a 52-week high of $1.8000 on 04/08/25 and a 52-week low of $0.7800 on 01/02/25.
Support And Resistance Levels for Lucid Diagnostics Inc (LUCD)
According to the 24-hour chart, there is a support level at 1.3034, which, if violated, would cause prices to drop to 1.2767. In the upper region, resistance lies at 1.3533. The next price resistance is at 1.3765. RSI (Relative Strength Index) is 55.51 on the 14-day chart, showing neutral technical sentiment.
